AR045582A1 - Piridinas pirazinas y pirimidinas heteroarilo fusionadas como ligandos receptores de crf1 - Google Patents
Piridinas pirazinas y pirimidinas heteroarilo fusionadas como ligandos receptores de crf1Info
- Publication number
- AR045582A1 AR045582A1 ARP040103174A ARP040103174A AR045582A1 AR 045582 A1 AR045582 A1 AR 045582A1 AR P040103174 A ARP040103174 A AR P040103174A AR P040103174 A ARP040103174 A AR P040103174A AR 045582 A1 AR045582 A1 AR 045582A1
- Authority
- AR
- Argentina
- Prior art keywords
- optionally substituted
- rings
- mono
- ring
- alkyl
- Prior art date
Links
- 102100038018 Corticotropin-releasing factor receptor 1 Human genes 0.000 title 1
- 101000878678 Homo sapiens Corticotropin-releasing factor receptor 1 Proteins 0.000 title 1
- KYQCOXFCLRTKLS-UHFFFAOYSA-N Pyrazine Chemical compound C1=CN=CC=N1 KYQCOXFCLRTKLS-UHFFFAOYSA-N 0.000 title 1
- 101000948733 Saccharomyces cerevisiae (strain ATCC 204508 / S288c) Probable phospholipid translocase non-catalytic subunit CRF1 Proteins 0.000 title 1
- 239000003446 ligand Substances 0.000 title 1
- 150000003230 pyrimidines Chemical class 0.000 title 1
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 abstract 12
- 229910052757 nitrogen Inorganic materials 0.000 abstract 10
- 125000001072 heteroaryl group Chemical class 0.000 abstract 8
- 229910052760 oxygen Inorganic materials 0.000 abstract 7
- 229910052717 sulfur Inorganic materials 0.000 abstract 6
- 125000005842 heteroatom Chemical group 0.000 abstract 5
- 229910052739 hydrogen Inorganic materials 0.000 abstract 5
- 239000001257 hydrogen Substances 0.000 abstract 5
- 150000002431 hydrogen Chemical group 0.000 abstract 5
- 125000000217 alkyl group Chemical group 0.000 abstract 4
- 229910052736 halogen Inorganic materials 0.000 abstract 4
- 150000002367 halogens Chemical group 0.000 abstract 4
- -1 tri-substituted, 1-naphthyl Chemical group 0.000 abstract 4
- 125000004103 aminoalkyl group Chemical group 0.000 abstract 3
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical group [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 abstract 3
- 125000001188 haloalkyl group Chemical group 0.000 abstract 3
- 239000001301 oxygen Substances 0.000 abstract 3
- 125000005017 substituted alkenyl group Chemical group 0.000 abstract 3
- 125000000547 substituted alkyl group Chemical group 0.000 abstract 3
- 125000004426 substituted alkynyl group Chemical group 0.000 abstract 3
- 125000005346 substituted cycloalkyl group Chemical group 0.000 abstract 3
- NINIDFKCEFEMDL-UHFFFAOYSA-N Sulfur Chemical compound [S] NINIDFKCEFEMDL-UHFFFAOYSA-N 0.000 abstract 2
- 125000004644 alkyl sulfinyl group Chemical group 0.000 abstract 2
- 125000004390 alkyl sulfonyl group Chemical group 0.000 abstract 2
- 125000004414 alkyl thio group Chemical group 0.000 abstract 2
- 125000004093 cyano group Chemical group *C#N 0.000 abstract 2
- 125000000449 nitro group Chemical group [O-][N+](*)=O 0.000 abstract 2
- 125000005415 substituted alkoxy group Chemical group 0.000 abstract 2
- 239000011593 sulfur Substances 0.000 abstract 2
- 125000001622 2-naphthyl group Chemical group [H]C1=C([H])C([H])=C2C([H])=C(*)C([H])=C([H])C2=C1[H] 0.000 abstract 1
- 208000024172 Cardiovascular disease Diseases 0.000 abstract 1
- 208000030814 Eating disease Diseases 0.000 abstract 1
- 208000019454 Feeding and Eating disease Diseases 0.000 abstract 1
- 125000003545 alkoxy group Chemical group 0.000 abstract 1
- 125000003118 aryl group Chemical group 0.000 abstract 1
- 208000015114 central nervous system disease Diseases 0.000 abstract 1
- 150000001875 compounds Chemical class 0.000 abstract 1
- 125000004122 cyclic group Chemical group 0.000 abstract 1
- 125000000753 cycloalkyl group Chemical group 0.000 abstract 1
- 125000005432 dialkylcarboxamide group Chemical group 0.000 abstract 1
- 235000014632 disordered eating Nutrition 0.000 abstract 1
- 230000002526 effect on cardiovascular system Effects 0.000 abstract 1
- 239000008194 pharmaceutical composition Substances 0.000 abstract 1
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 abstract 1
- 150000003839 salts Chemical class 0.000 abstract 1
- 229920006395 saturated elastomer Polymers 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/04—Ortho-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/22—Anxiolytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/24—Antidepressants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
- C07D487/04—Ortho-condensed systems
Landscapes
- Chemical & Material Sciences (AREA)
- Health & Medical Sciences (AREA)
- Organic Chemistry (AREA)
- Veterinary Medicine (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Engineering & Computer Science (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Pharmacology & Pharmacy (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Neurology (AREA)
- Biomedical Technology (AREA)
- Neurosurgery (AREA)
- Psychiatry (AREA)
- Pain & Pain Management (AREA)
- Heart & Thoracic Surgery (AREA)
- Cardiology (AREA)
- Child & Adolescent Psychology (AREA)
- Diabetes (AREA)
- Hematology (AREA)
- Obesity (AREA)
- Epidemiology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Plural Heterocyclic Compounds (AREA)
- Investigating Or Analysing Biological Materials (AREA)
- Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
Abstract
Composiciones farmacéuticas que los comprenden y usos para el tratamiento de desórdenes del SNC, cardiovasculares y de la alimentación. Reivindicación 1: Un compuesto de fórmula (1), o una sal farmacéuticamente aceptable del mismo, en el cual: Ar se elige entre: fenilo que está mono-, di- o tri-sustituido, 1-naftilo y 2-naftilo, cada uno de los cuales está opcionalmente mono-, di- o tri-sustituido y heteroarilo opcionalmente mono-, di- o tri-sustituido, teniendo dicho heteroarilo de 1 a 3 anillos, 5 a 7 miembros de anillo en cada anillo, y, por lo menos uno de dichos anillos, desde 1 hasta aproximadamente 3 heteroátomos seleccionados del grupo formado por N, O y S; R es oxígeno o está ausente; el grupo de fórmula (2), representa un sistema anular de 5 miembros saturado, insaturado o aromático que contiene 0 ó 1 heteroátomos, en el cual: Z1 es CR1, CR1R1', nitrógeno o NR1''; Z2 es nitrógeno, oxígeno, azufre, CR2, CR2R2' o NR2''; Z3 es nitrógeno, oxígeno, azufre, CR3, CR3R3' o NR3''; R1 se elige entre hidrógeno, halógeno, hidroxi, ciano, amino, alquilo opcionalmente sustituido, alquenilo opcionalmente sustituido, alquinilo opcionalmente sustituido, alcoxi opcionalmente sustituido, mono- o di-alquilamino opcionalmente sustituido, cicloalquilo opcionalmente sustituido, (cicloalquil)alquilo opcionalmente sustituido, alquiltio opcionalmente sustituido, alquilsulfinilo opcionalmente sustituido, alquilsulfonilo opcionalmente sustituido, mono- o dialquilcarboxamida opcionalmente sustituida, arilo carbocíclico opcionalmente sustituido y heteroarilo opcionalmente sustituido, teniendo dicho heteroarilo opcionalmente sustituido de 1 a 3 anillos, 5 a 7 miembros de anillo en cada anillo y, en por lo menos uno de dichos anillos, desde 1 hasta aproximadamente 3 heteroátomos seleccionados del grupo formado por N, O y S; R1'' se elige entre alquilo opcionalmente sustituido, alquenilo opcionalmente sustituido, alquinilo opcionalmente sustituido, (cicloalquil)alquilo opcionalmente sustituido y arilo carbocíclico opcionalmente sustituido y heteroarilo opcionalmente sustituido, teniendo dicho heteroarilo opcionalmente sustituido de 1 a 3 anillos, 5 a 7 miembros de anillo en cada anillo y, en por lo menos uno de dichos anillos, desde 1 hasta aproximadamente 3 heteroátomos seleccionados del grupo formado por N, O y S; R2 y R3 se eligen independientemente entre hidrógeno, halógeno, hidroxi, amino, ciano, nitro, alquilo, haloalquilo, alcoxi, aminoalquilo y mono- y di-alquilamino; R1', R2' y R3' se eligen independientemente entre hidrógeno, halógeno, alquilo, haloalquilo y aminoalquilo; R2'' y R3'' se eligen independientemente entre hidrógeno, alquilo, haloalquilo y aminoalquilo; Z4 es nitrógeno o CR4; Z5 es nitrógeno o CR5; donde Z4 y Z5 no son ambos nitrógeno; y R4 y R5 se eligen independientemente entre hidrógeno, halógeno, hidroxi, amino, ciano, nitro, alquilo opcionalmente sustituido, alquenilo opcionalmente sustituido, alquinilo opcionalmente sustituido, alcoxi opcionalmente sustituido, mono- o di-alquilamino opcionalmente sustituido, (cicloalquil)alquilo opcionalmente sustituido, alquiltio opcionalmente sustituido, alquilsulfinilo opcionalmente sustituido, alquilsulfonilo opcionalmente sustituido, mono- o di-alquilcarboxamida opcionalmente sustituida, arilo carbocíclico opcionalmente sustituido y heteroarilo opcionalmente sustituido, teniendo donde dicho heteroarilo opcionalmente sustituido de 1 a 3 anillos, 5 a 7 miembros de anillo en cada anillo y, en por lo menos uno de dichos anillos, desde 1 hasta aproximadamente 3 heteroátomos seleccionados del grupo formado por N, O y S.
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US50041403P | 2003-09-05 | 2003-09-05 |
Publications (1)
Publication Number | Publication Date |
---|---|
AR045582A1 true AR045582A1 (es) | 2005-11-02 |
Family
ID=34272952
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
ARP040103174A AR045582A1 (es) | 2003-09-05 | 2004-09-03 | Piridinas pirazinas y pirimidinas heteroarilo fusionadas como ligandos receptores de crf1 |
Country Status (19)
Country | Link |
---|---|
US (2) | US20050113379A1 (es) |
EP (1) | EP1680424A2 (es) |
JP (1) | JP2007504271A (es) |
KR (1) | KR20060088534A (es) |
CN (1) | CN1878773A (es) |
AP (1) | AP2006003559A0 (es) |
AR (1) | AR045582A1 (es) |
AU (1) | AU2004270713A1 (es) |
BR (1) | BRPI0414087A (es) |
CA (1) | CA2537829A1 (es) |
CR (1) | CR8274A (es) |
EA (1) | EA200600372A1 (es) |
EC (1) | ECSP066408A (es) |
IL (1) | IL174084A0 (es) |
MA (1) | MA28086A1 (es) |
NO (1) | NO20061180L (es) |
TW (1) | TW200530232A (es) |
WO (1) | WO2005023806A2 (es) |
ZA (1) | ZA200601978B (es) |
Families Citing this family (73)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP1675858A2 (en) * | 2003-09-03 | 2006-07-05 | Neurogen Corporation | 5-aryl-pyrazolo [4,3-d] pyrimidines, pyridines, and pyrazines and related compounds |
CN103467471A (zh) | 2005-06-06 | 2013-12-25 | 武田药品工业株式会社 | 有机化合物 |
JP2009506006A (ja) * | 2005-08-25 | 2009-02-12 | エフ.ホフマン−ラ ロシュ アーゲー | p38MAPキナーゼ阻害剤およびその使用方法 |
EP1932839A4 (en) * | 2005-09-06 | 2014-09-10 | Shionogi & Co | INDOLECARBOXYLATE ACID DERIVATIVE HAVING ANTAGONIST EFFECT OF THE PGD2 RECEPTOR |
US7405302B2 (en) * | 2005-10-11 | 2008-07-29 | Amira Pharmaceuticals, Inc. | 5-lipoxygenase-activating protein (FLAP) inhibitors |
GB2431927B (en) | 2005-11-04 | 2010-03-17 | Amira Pharmaceuticals Inc | 5-Lipoxygenase-activating protein (FLAP) inhibitors |
US7977359B2 (en) | 2005-11-04 | 2011-07-12 | Amira Pharmaceuticals, Inc. | 5-lipdxygenase-activating protein (FLAP) inhibitors |
US8399666B2 (en) | 2005-11-04 | 2013-03-19 | Panmira Pharmaceuticals, Llc | 5-lipoxygenase-activating protein (FLAP) inhibitors |
EP3208272B1 (en) | 2005-11-08 | 2020-01-08 | Vertex Pharmaceuticals Incorporated | Heterocyclic modulators of atp-binding cassette transporters |
GB0525068D0 (en) | 2005-12-08 | 2006-01-18 | Novartis Ag | Organic compounds |
EP1961754A4 (en) | 2005-12-15 | 2009-11-11 | Ono Pharmaceutical Co | BICYCLIC HETEROCYCLIC COMPOUND |
TW200812588A (en) * | 2006-05-15 | 2008-03-16 | Neurogen Corp | CRF1 receptor ligands comprising heteroaryl fused bicycles |
TWI398252B (zh) | 2006-05-26 | 2013-06-11 | Novartis Ag | 吡咯并嘧啶化合物及其用途 |
WO2008070095A1 (en) | 2006-12-05 | 2008-06-12 | Intra-Cellular Therapies, Inc. | Novel uses |
WO2008076446A1 (en) * | 2006-12-18 | 2008-06-26 | Coleman Peter R | Accelerated opiate dependence detoxification process |
EP2091952A1 (en) * | 2006-12-19 | 2009-08-26 | F. Hoffmann-Roche AG | Pyrazolo ý3, 4 -d¨pyrimidine p38 map kinase inhibitors |
WO2008083070A1 (en) * | 2006-12-29 | 2008-07-10 | Neurogen Corporation | Crf1 receptor ligands comprising fused bicyclic heteroaryl moieties |
EP2164840A2 (en) | 2007-05-09 | 2010-03-24 | Vertex Pharmaceuticals Incorporated | Modulators of cftr |
US8846693B2 (en) * | 2007-12-06 | 2014-09-30 | Intra-Cellular Therapies, Inc. | Optionally substituted pyrazolo[3,4-d]pyrimidine-4,6-diones |
EA201070700A1 (ru) * | 2007-12-07 | 2011-06-30 | Вертекс Фармасьютикалз Инкорпорейтед | Способы получения циклоалкилкарбоксамидопиридинбензойных кислот |
RS55559B1 (sr) | 2007-12-07 | 2017-05-31 | Vertex Pharma | Čvrste forme 3-(6-(1-(2,2-difluorobenzo[d][1,3]dioksol-5-il)ciklopropankarboksamido)-3-metilpiridin-2-il) benzoeve kiseline |
JP5523352B2 (ja) | 2008-02-28 | 2014-06-18 | バーテックス ファーマシューティカルズ インコーポレイテッド | Cftr修飾因子としてのへテロアリール誘導体 |
KR20160129109A (ko) | 2008-05-23 | 2016-11-08 | 아미라 파마슈티칼스 인코포레이티드 | 5-리폭시게나아제 활성화 단백질 억제제 |
CA2734802C (en) | 2008-08-22 | 2016-05-31 | Novartis Ag | Pyrrolopyrimidine compounds as cdk inhibitors |
MX2011005937A (es) | 2008-12-06 | 2011-12-16 | Intra Cellular Therapies Inc | Compuestos organicos. |
MX2011005936A (es) * | 2008-12-06 | 2011-12-16 | Intra Cellular Therapies Inc | Compuestos organicos. |
EP2367428B1 (en) | 2008-12-06 | 2016-04-06 | Intra-Cellular Therapies, Inc. | Organic compounds |
EP2367429B1 (en) | 2008-12-06 | 2017-06-07 | Intra-Cellular Therapies, Inc. | Organic compounds |
GEP20146046B (en) | 2008-12-06 | 2014-02-25 | Intracellular Therapies Inc | Organic compounds |
MA32940B1 (fr) | 2008-12-06 | 2012-01-02 | Intra Cellular Therapies Inc | Composes organiques |
US8349852B2 (en) | 2009-01-13 | 2013-01-08 | Novartis Ag | Quinazolinone derivatives useful as vanilloid antagonists |
WO2010096426A2 (en) * | 2009-02-20 | 2010-08-26 | Emory University | Compounds, compositions, methods of synthesis, and methods of treatment |
JP2012526810A (ja) | 2009-05-13 | 2012-11-01 | イントラ−セルラー・セラピーズ・インコーポレイテッド | 有機化合物 |
WO2011092293A2 (en) | 2010-02-01 | 2011-08-04 | Novartis Ag | Cyclohexyl amide derivatives as crf receptor antagonists |
US20120295942A1 (en) | 2010-02-01 | 2012-11-22 | Nicholas James Devereux | Pyrazolo[5,1b]oxazole Derivatives as CRF-1 Receptor Antagonists |
JP5748777B2 (ja) | 2010-02-02 | 2015-07-15 | ノバルティス アーゲー | Crf受容体アンタゴニストとしてのシクロヘキシルアミド誘導体 |
UY33227A (es) | 2010-02-19 | 2011-09-30 | Novartis Ag | Compuestos de pirrolopirimidina como inhibidores de la cdk4/6 |
NZ602838A (en) | 2010-04-07 | 2015-06-26 | Vertex Pharma | Pharmaceutical compositions of 3-(6-(1-(2,2-difluorobenzo[d][1,3]dioxol-5-yl) cyclopropanecarboxamido)-3-methylpyridin-2-yl)benzoic acid and administration thereof |
WO2011153138A1 (en) | 2010-05-31 | 2011-12-08 | Intra-Cellular Therapies, Inc. | Organic compounds |
EP2590657A4 (en) | 2010-05-31 | 2014-02-12 | Intra Cellular Therapies Inc | ORGANIC COMPOUNDS |
TW201206937A (en) | 2010-05-31 | 2012-02-16 | Intra Cellular Therapies Inc | Organic compounds |
JP5879336B2 (ja) | 2010-05-31 | 2016-03-08 | イントラ−セルラー・セラピーズ・インコーポレイテッドIntra−Cellular Therapies, Inc. | 有機化合物 |
CN103442568A (zh) | 2010-10-08 | 2013-12-11 | Abbvie公司 | 呋喃并[3,2-d]嘧啶化合物 |
US8546416B2 (en) | 2011-05-27 | 2013-10-01 | Novartis Ag | 3-spirocyclic piperidine derivatives as ghrelin receptor agonists |
WO2012171016A1 (en) | 2011-06-10 | 2012-12-13 | Intra-Cellular Therapies, Inc. | Organic compounds |
ES2644781T3 (es) * | 2012-03-06 | 2017-11-30 | Bayer Intellectual Property Gmbh | Azabiciclos sustituidos y su uso |
JP2015525202A (ja) | 2012-05-03 | 2015-09-03 | ノバルティス アーゲー | グレリン受容体アゴニストとしての2,7−ジアザ−スピロ[4,5]デカ−7−イル誘導体のl−リンゴ酸塩およびその結晶形態 |
WO2014127331A1 (en) | 2013-02-17 | 2014-08-21 | Intra-Cellular Therapies, Inc. | Novel uses |
EP3479825B1 (en) | 2013-03-15 | 2021-02-17 | Intra-Cellular Therapies, Inc. | Pde1 inhibitors for use in the treatment and/or prevention of cns or pns diseases or disorders |
MX2015013042A (es) | 2013-03-15 | 2016-05-05 | Intra Cellular Therapies Inc | Compuestos organicos. |
JP6963896B2 (ja) | 2013-11-12 | 2021-11-10 | バーテックス ファーマシューティカルズ インコーポレイテッドVertex Pharmaceuticals Incorporated | Cftr媒介性疾患の処置のための医薬組成物を調製する方法 |
EA031804B1 (ru) | 2014-02-03 | 2019-02-28 | Вайтаи Фармасьютиклз, Инк. | Дигидропирролопиридиновые ингибиторы ror-гамма |
EP2940022B1 (en) * | 2014-04-30 | 2020-09-02 | Masarykova Univerzita | Furopyridines as inhibitors of protein kinases |
ES2732442T3 (es) | 2014-06-20 | 2019-11-22 | Intra Cellular Therapies Inc | Compuestos orgánicos |
US10285992B2 (en) | 2014-08-07 | 2019-05-14 | Intra-Cellular Therapies, Inc. | Combinations of PDE1 inhibitors and NEP inhibitors and associated methods |
JP6591530B2 (ja) | 2014-08-07 | 2019-10-16 | イントラ−セルラー・セラピーズ・インコーポレイテッドIntra−Cellular Therapies, Inc. | 有機化合物 |
US10150774B2 (en) | 2014-09-17 | 2018-12-11 | Intra-Cellular Therapies, Inc. | Compounds and methods |
JP6564029B2 (ja) | 2014-10-14 | 2019-08-21 | ヴァイティー ファーマシューティカルズ,エルエルシー | Ror−ガンマのジヒドロピロロピリジン阻害剤 |
US9663515B2 (en) | 2014-11-05 | 2017-05-30 | Vitae Pharmaceuticals, Inc. | Dihydropyrrolopyridine inhibitors of ROR-gamma |
US9845308B2 (en) | 2014-11-05 | 2017-12-19 | Vitae Pharmaceuticals, Inc. | Isoindoline inhibitors of ROR-gamma |
RU2691136C2 (ru) | 2014-11-18 | 2019-06-11 | Вертекс Фармасьютикалз Инкорпорейтед | Способ проведения высокопроизводительной тестовой высокоэффективной жидкостной хроматографии |
TW201625635A (zh) | 2014-11-21 | 2016-07-16 | 默沙東藥廠 | 作為可溶性鳥苷酸環化酶活化劑之***并吡基衍生物 |
ES2856931T3 (es) | 2015-08-05 | 2021-09-28 | Vitae Pharmaceuticals Llc | Moduladores de ROR-gamma |
EP3377482B1 (en) | 2015-11-20 | 2021-05-12 | Vitae Pharmaceuticals, LLC | Modulators of ror-gamma |
TW202220968A (zh) | 2016-01-29 | 2022-06-01 | 美商維它藥物有限責任公司 | ROR-γ調節劑 |
WO2017172795A1 (en) | 2016-03-28 | 2017-10-05 | Intra-Cellular Therapies, Inc. | Novel compositions and methods |
US9481674B1 (en) | 2016-06-10 | 2016-11-01 | Vitae Pharmaceuticals, Inc. | Dihydropyrrolopyridine inhibitors of ROR-gamma |
EP3510029A4 (en) * | 2016-09-07 | 2020-03-11 | The Regents of The University of California | ALLOSTERIC CORTICOTROPIN RELEASING FACTOR-1 (CRFR1) ANTAGONISTS TO REDUCE P-TAU AND IMPROVE THE COGNITION |
EP3509589B1 (en) | 2016-09-12 | 2021-11-17 | Intra-Cellular Therapies, Inc. | Novel uses |
WO2019018975A1 (en) | 2017-07-24 | 2019-01-31 | Vitae Pharmaceuticals, Inc. | INHIBITORS OF ROR GAMMA |
AR112461A1 (es) | 2017-07-24 | 2019-10-30 | Vitae Pharmaceuticals Inc | PROCESOS PARA LA PRODUCCIÓN DE SALES Y FORMAS CRISTALINAS DE INHIBIDORES DE RORg |
JP7401442B2 (ja) | 2018-01-31 | 2023-12-19 | イントラ-セルラー・セラピーズ・インコーポレイテッド | 新規使用 |
CN110437846B (zh) * | 2019-08-30 | 2022-02-25 | 陕西师范大学 | 含炔键的氟取代苯并噁唑液晶化合物及其制备方法 |
Family Cites Families (8)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP3398152B2 (ja) * | 1993-10-12 | 2003-04-21 | ブリストル‐マイヤーズ・スクイブ・ファーマ・カンパニー | 1n−アルキル−n−アリールピリミジンアミンおよびその誘導体 |
ATE182148T1 (de) * | 1995-05-12 | 1999-07-15 | Neurogen Corp | Neue deazapurinderivate; eine neue klasse von crf1-spezifischen liganden |
JP3964478B2 (ja) * | 1995-06-30 | 2007-08-22 | エーザイ・アール・アンド・ディー・マネジメント株式会社 | ヘテロ環含有カルボン酸誘導体及びそれを含有する医薬 |
CA2263566C (en) * | 1996-08-28 | 2003-09-09 | Pfizer Inc. | Substituted 6,5-hetero-bicyclic derivatives |
JP2002510687A (ja) * | 1998-04-02 | 2002-04-09 | ニューロゲン コーポレイション | アミノアルキル置換ピロロ[2,3−b]ピリジンおよびピロロ[2,3−d]ピリミジン誘導体:crf1レセプタのモジュレータ |
WO2002000623A2 (en) * | 2000-06-26 | 2002-01-03 | Neurogen Corporation | Aryl fused substituted 4-oxy-pyridines |
DE10229777A1 (de) * | 2002-07-03 | 2004-01-29 | Bayer Ag | Indolin-Phenylsulfonamid-Derivate |
US7638530B2 (en) * | 2003-04-24 | 2009-12-29 | Merck & Co., Inc. | Inhibitors of Akt activity |
-
2004
- 2004-09-03 ZA ZA200601978A patent/ZA200601978B/en unknown
- 2004-09-03 CN CNA2004800327037A patent/CN1878773A/zh active Pending
- 2004-09-03 US US10/933,834 patent/US20050113379A1/en not_active Abandoned
- 2004-09-03 CA CA002537829A patent/CA2537829A1/en not_active Abandoned
- 2004-09-03 WO PCT/US2004/028899 patent/WO2005023806A2/en active Application Filing
- 2004-09-03 EP EP04788585A patent/EP1680424A2/en not_active Withdrawn
- 2004-09-03 JP JP2006526210A patent/JP2007504271A/ja active Pending
- 2004-09-03 EA EA200600372A patent/EA200600372A1/ru unknown
- 2004-09-03 AP AP2006003559A patent/AP2006003559A0/xx unknown
- 2004-09-03 AU AU2004270713A patent/AU2004270713A1/en not_active Abandoned
- 2004-09-03 AR ARP040103174A patent/AR045582A1/es unknown
- 2004-09-03 BR BRPI0414087-7A patent/BRPI0414087A/pt not_active IP Right Cessation
- 2004-09-03 KR KR1020067004564A patent/KR20060088534A/ko not_active Application Discontinuation
- 2004-09-06 TW TW093126841A patent/TW200530232A/zh unknown
-
2006
- 2006-03-02 IL IL174084A patent/IL174084A0/en unknown
- 2006-03-03 EC EC2006006408A patent/ECSP066408A/es unknown
- 2006-03-03 CR CR8274A patent/CR8274A/es unknown
- 2006-03-14 NO NO20061180A patent/NO20061180L/no not_active Application Discontinuation
- 2006-03-24 US US11/389,646 patent/US20060199823A1/en not_active Abandoned
- 2006-04-05 MA MA28916A patent/MA28086A1/fr unknown
Also Published As
Publication number | Publication date |
---|---|
TW200530232A (en) | 2005-09-16 |
IL174084A0 (en) | 2008-02-09 |
CR8274A (es) | 2008-06-10 |
AU2004270713A1 (en) | 2005-03-17 |
CA2537829A1 (en) | 2005-03-17 |
ZA200601978B (en) | 2007-05-30 |
ECSP066408A (es) | 2006-09-18 |
AP2006003559A0 (en) | 2006-04-30 |
EP1680424A2 (en) | 2006-07-19 |
BRPI0414087A (pt) | 2006-10-31 |
WO2005023806A3 (en) | 2005-06-02 |
MA28086A1 (fr) | 2006-08-01 |
WO2005023806A2 (en) | 2005-03-17 |
CN1878773A (zh) | 2006-12-13 |
EA200600372A1 (ru) | 2006-08-25 |
US20050113379A1 (en) | 2005-05-26 |
US20060199823A1 (en) | 2006-09-07 |
JP2007504271A (ja) | 2007-03-01 |
NO20061180L (no) | 2006-03-31 |
KR20060088534A (ko) | 2006-08-04 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
AR045582A1 (es) | Piridinas pirazinas y pirimidinas heteroarilo fusionadas como ligandos receptores de crf1 | |
AR066111A1 (es) | Compuesto triciclico de imidazol, su uso para preparar un medicamento, composicion farmaceutica que lo comprende y compuestos intermediarios en la sintesis de dicho compuesto | |
EA200800737A1 (ru) | Поперечно связанные соединения циклических аминов и средства для борьбы с вредителями | |
EA202190137A1 (ru) | Нафтиридиноновые соединения для применения в качестве активаторов t-клеток | |
GT200600165A (es) | Derivados dihidrobenzofuranos y usos de los mismos | |
AR058587A1 (es) | Compuestos de pirrolo-1,5-naftiridinona,su uso como agentes antibacterianos, composiciones farmaceuticas que los contienen y compuestos intermediarios para preparar dichos compuestos | |
PE20070832A1 (es) | Derivados de piridazinona como inhibidores de la tirosina quinasa | |
AR087046A2 (es) | Compuestos derivados de 4-oxoquinolina | |
AR054799A1 (es) | Derivados de oxindol | |
TW200800949A (en) | Macrocylic inhibitors of hepatitis C virus | |
AR046244A1 (es) | Activadores de glucoquinasa heteroaromaticos de seis miembros 5- sustituidos | |
AR057380A1 (es) | Compuestos quimicos derivados de 2-azetidinona y uso terapeutico de los mismos | |
PE20011047A1 (es) | Compuesto de amida y composiciones farmaceuticas para inhibir proteinquinasas | |
AR040076A1 (es) | Derivados de piridazin-3(2h)-ona | |
MY152153A (en) | Macrocylic inhibitors of hepatitis c virus | |
AR054035A1 (es) | Derivados benzodioxano y benzodioxolano y uso de los mismos | |
UY29703A1 (es) | "inhibidores macrocíclicos del virus de la hepatitis c" | |
AR050913A1 (es) | Compuestos derivados de tiazolpiridina como activadores de glucoquinasa; composiciones farmaceuticas que los contienen y su uso en medicamentos para el tratamiento de la diabetes tipo ii | |
DK1778677T3 (da) | Heterocykliske kondenserede forbindelser der er egnede som antidiuretiske midler | |
AR037907A1 (es) | Derivados de azaindolilalquilamina como ligandos de 5-hidroxitriptamina-6 | |
RS50737B (sr) | Beta-amino tetrahidroimidazo (1,2-a)pirazini i tetrahidrotriazolo(4,3-a)pirazini kao inhibitori dipeptidil peptidaze u lečenju ili prevenciji dijabetesa | |
AR049276A1 (es) | Compuestos carboxamidos opiodes y composiciones farmaceuticas que los contienen | |
AR109868A1 (es) | Derivados heterocíclicos activos como plaguicidas con sustituyentes con azufre e hidroxilamina | |
ECSP109958A (es) | Derivados de pirimidina 934 | |
AR033379A1 (es) | Compuestos de difenilurea, procedimiento para su preparacion y composiciones farmaceuticas que los contienen |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
FB | Suspension of granting procedure |